Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Detects More High-Risk Prostate Cancers Than PSA

By LabMedica International staff writers
Posted on 24 Jun 2026

Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. More...

Prostate-specific antigen (PSA) testing can miss aggressive cancers while triggering unnecessary workups. More accurate blood-based risk assessment could improve triage and reduce avoidable procedures. A new study shows that the Stockholm3 blood test detected more high-risk prostate cancers than PSA in a large, population-based cohort.

Karolinska Institutet evaluated the Stockholm3 blood test against prostate-specific antigen (PSA) testing. The blood-based Stockholm3 test identified significantly more aggressive prostate cancers than traditional PSA without subjecting more men to unnecessary testing. The findings were published in Annals of Internal Medicine on June 23, 2026.

In a population-based study of 12,670 men aged 50–74 years, Stockholm3 detected 90% of aggressive cancer cases compared with 74% for PSA. The work draws on the STHLM3–MRI study framework. All participants underwent both tests and were followed for two years through national cancer registries to ascertain cancers missed at initial screening.

During follow-up, 443 men were diagnosed with clinically significant, or aggressive, prostate cancer. Stockholm3 missed significantly fewer serious cases than PSA, while the proportion of men incorrectly classified as high risk was similar between tests. The researchers note that longer-term follow-up is needed to determine effects on mortality and long-term outcomes.

“These results point toward a potential change in how prostate cancer screening can be conducted. A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures,” said Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet.

"The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are truly dangerous. Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA, without increasing the number of unnecessary follow-ups," said Palsdottir.

Related Links
Karolinska Institutet


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.